Medicare AdvantageCoverageMedium impact
MA06.013e, Serodiagnosis of Inflammatory Bowel Disease (IBD) and the Prometheus® IBD sgi Diagnostic™ Test
Independence Blue Cross·Gastroenterology, Internal Medicine, Family Medicine·Pharmacy
Effective date
Jul 9, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA06.013e regarding Serodiagnosis of Inflammatory Bowel Disease and Prometheus IBD sgi Diagnostic Test has been reissued with an effective date of July 9, 2025. The policy was posted and removed on September 9, 2025, indicating this may be a temporary or corrected version.
Action Required
By July 9, 2025: Billing team should monitor for the full policy details when they become available, as this summary indicates a reissued policy for IBD diagnostic testing that may affect prior authorization or coverage requirements. Verify current billing practices for Prometheus IBD sgi Diagnostic testing align with updated Medicare Advantage guidelines.